NCT03610880View on ClinicalTrials.gov

To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Chinese Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 17, 2017

Primary Completion Date

February 5, 2018

Study Completion Date

February 5, 2018

Conditions
Healthy Chinese Volunteers
Interventions
DRUG

TG-2349 (400 mg) plus DAG181 (200 mg)

Dosing period 1 (Day 1 to 7): TG-2349 400 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg

DRUG

DAG181 (200 mg) plus TG-2349 (400 mg)

Dosing period 1 (Day 1 to 7): DAG181 200 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg

Trial Locations (1)

Unknown

Xiangya Hospital Central South University, Changsha

All Listed Sponsors
collaborator

R&G Pharma Studies Co.,Ltd.

INDUSTRY

lead

Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT03610880 - To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Chinese Volunteers | Biotech Hunter | Biotech Hunter